Zeynep Eroglu News Today

Zeynep Eroglu, MD, discusses a phase 1/2 trial that evaluated ceritinib alone and in combination with trametinib in patients with mutant melanoma.

Zeynep Eroglu, MD, discusses the efficacy and safety of ceritinib as monotherapy and in combination with trametinib in pretreated advanced melanoma.

Zeynep Eroglu, MD, discusses how findings from a phase 1/2 study of ceritinib and trametinib could help inform future research in melanoma.

Zeynep Eroglu, MD, discusses the safety profile of ceritinib plus trametinib in pretreated metastatic melanoma.

Zeynep Eroglu, MD, discusses future steps for assessing ceritinib in combination with trametinib in patients with metastatic melanoma.

Zeynep Eroglu, MD, explains the rationale for adding navitoclax to dabrafenib plus trametinib in the treatment of patients with BRAF V600–mutant metastatic melanoma, highlights the methodologies and results of the CTEP-P9466 trial, and describes the implications of this research for this patient population.

The combination of dabrafenib and trametinib plus navitoclax generated responses and met the co-primary end point for complete response rate vs historical controls in patients with BRAF V600–mutant metastatic melanoma.

Data from a national clinical trial shows that a striking 89% of patients with desmoplastic melanoma responded to immunotherapy (pembrolizumab) alone, suggesting that many patients could avoid the risk for toxicity from combination therapies and achieve cancer control with this approach to treatment.

'One of the highest tumor response rates we've seen in any cancer,' study discussant says

Close to 90 percent of patients with unresectable (inoperable) desmoplastic melanoma, a rare form of skin cancer, saw their cancer improve after treatment with the immunotherapy drug pembrolizumab in a recent clinical trial. These results from the S1512 trial are being delivered in an oral presentation at the clinical trials plenary session of the 2023 annual meeting of the American Association for Cancer Research (AACR) in Orlando, Florida, on April 16th.